← Browse by Condition
Medical Condition

mds

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for mds sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — mds Clinical Trials

How many clinical trials are currently recruiting for mds?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for mds, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for mds?
mds research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a mds clinical trial?
Eligibility criteria for mds trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
Groupe Francophone des Myelodysplasies 1 trial
Cullgen (Shanghai),Inc 1 trial
LMU Klinikum 1 trial
University Hospital, Akershus 1 trial

Recruiting Clinical Trials

NCT05181735 Phase 1, Phase 2
Recruiting
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Enrollment
150 pts
Location
France, Italy
Sponsor
Groupe Francophone des Myelody...
View Trial →
NCT07347171 Phase 1
Recruiting
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Enrollment
45 pts
Location
China
Sponsor
Cullgen (Shanghai),Inc
View Trial →
NCT05554835
Recruiting
Global Registry and Natural History Study for Mitochondrial Disorders
Enrollment
6,000 pts
Location
Austria, Germany, It...
Sponsor
LMU Klinikum
View Trial →
NCT05025098 Phase 2
Recruiting
Precision Therapy Versus Standard Therapy in AML and MDS in Elderly
Enrollment
36 pts
Location
Norway
Sponsor
University Hospital, Akershus
View Trial →

Related Conditions

myelodysplastic syndromes (1) leukemia (1) aml (1) aml acute myelogenous leukemia (1) mds myelodysplastic syndrome (1) mitochondrial diseases (1) kearns sayre syndrome (1) midd (1) sando (1) scae (1) narp syndrome (1) melas syndrome (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology